Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnus, Clara Luzia, Hiergeist, Andreas, Schuster, Philipp, Rohrhofer, Anette, Medenbach, Jan, Gessner, André, Peterhoff, David, Schmidt, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449809/
https://www.ncbi.nlm.nih.gov/pubmed/36090991
http://dx.doi.org/10.3389/fimmu.2022.966236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449809/
https://www.ncbi.nlm.nih.gov/pubmed/36090991
http://dx.doi.org/10.3389/fimmu.2022.966236

Ejemplares similares